{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:05:55Z","timestamp":1769753155778,"version":"3.49.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,2]],"date-time":"2013-09-02T00:00:00Z","timestamp":1378080000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Ropinirole prolonged release (RPR) is a once-daily formulation. However, there may be individual pharmacokinetic differences so that multiple dosing may be preferred in some individuals. This study compares once-daily and twice-daily RPR in patients with Parkinson\u2019s disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study was an open-label crossover study. We enrolled Parkinson\u2019s disease patients on dopamine agonist therapy with unsatisfactory control such as motor fluctuation, dyskinesia and sleep-related problems. Agonists were switched into equivalent dose of RPR. Subjects were consecutively enrolled into either once-daily first or twice-daily first groups, and received the same amount of RPR in a single and two divided dosing for 8\u00a0weeks respectively in a crossover manner without a washout period.<\/jats:p>\n            <jats:p>The primary outcome was a questionnaire of the preference completed by patients in the last visit. The secondary outcome measures included the Unified Parkinson\u2019s Disease Rating Scale part 3 (mUPDRS), Hoehn and Yahr stage (H&amp;Y); sleep questionnaire including overall quality of sleep, nocturnal off symptoms and early morning symptoms; Epworth Sleep Scale (ESS); compliances and patient global impression (PGI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 82 patients were enrolled and 61 completed the study. 31 patients preferred twice-daily regimen, 17 preferred the once-daily regimen, and 13 had no preference. Their mean mUPDRS, H&amp;Y, ESS, sleep quality, compliance and adverse events were not statistically different in both regimens. PGI-improvement on wearing off defined was better in twice-daily dosing regimen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>RPR is a once-daily formulation, but multiple dosing was preferred in many patients. Multiple dosing of RPR might be a therapeutic option if once-daily dosing is unsatisfactory.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>This study is registered with ClinicalTrials.gov, number <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/NCT00986245\" ext-link-type=\"uri\">NCT00986245<\/jats:ext-link>.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2377-13-113","type":"journal-article","created":{"date-parts":[[2013,9,2]],"date-time":"2013-09-02T18:14:11Z","timestamp":1378145651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson\u2019s disease"],"prefix":"10.1186","volume":"13","author":[{"given":"Ji Young","family":"Yun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Seon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beom S","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,2]]},"reference":[{"issue":"11 Suppl 4","key":"839_CR1","first-page":"S13","volume":"55","author":"JA Obeso","year":"2000","unstructured":"Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW: The evolution and origin of motor complications in Parkinson\u2019s disease. Neurology. 2000, 55 (11 Suppl 4): S13-S20. discussion S21-13","journal-title":"Neurology"},{"issue":"10","key":"839_CR2","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1185\/03007990802387130","volume":"24","author":"F Stocchi","year":"2008","unstructured":"Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Ease PDMSI: Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson\u2019s disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin. 2008, 24 (10): 2883-2895. 10.1185\/03007990802387130.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"839_CR3","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/mds.23498","volume":"26","author":"F Stocchi","year":"2011","unstructured":"Stocchi F, Giorgi L, Hunter B, Schapira AH: PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson\u2019s disease. Mov Disord. 2011, 26 (7): 1259-1265. 10.1002\/mds.23498.","journal-title":"Mov Disord"},{"issue":"6","key":"839_CR4","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/mds.22112","volume":"24","author":"D Grosset","year":"2009","unstructured":"Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, Cubo E, Martinez-Martin P, Rascol O, Negre-Pages L, et al: Adherence to antiparkinson medication in a multicenter European study. Mov Disord. 2009, 24 (6): 826-832. 10.1002\/mds.22112.","journal-title":"Mov Disord"},{"issue":"12","key":"839_CR5","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1016\/j.clinthera.2007.12.010","volume":"29","author":"DJ Tompson","year":"2007","unstructured":"Tompson DJ, Vearer D: Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson\u2019s disease. Clin Ther. 2007, 29 (12): 2654-2666. 10.1016\/j.clinthera.2007.12.010.","journal-title":"Clin Ther"},{"issue":"Suppl 5","key":"839_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00415-008-5008-z","volume":"255","author":"WH Jost","year":"2008","unstructured":"Jost WH, Buhmann C, Fuchs G, Greulich W, Hummel S, Korchounov A, Mungersdorf M, Schwarz M, Spiegel-Meixensberger M: Initial experience with ropinirole PR (prolonged release). J Neurol. 2008, 255 (Suppl 5): 60-63.","journal-title":"J Neurol"},{"issue":"Suppl 4","key":"839_CR7","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/S1353-8020(09)70842-9","volume":"15","author":"M Onofrj","year":"2009","unstructured":"Onofrj M, Bonanni L, De Angelis MV, Anzellotti F, Ciccocioppo F, Thomas A: Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies. Parkinsonism Relat Disord. 2009, 15 (Suppl 4): S85-S92.","journal-title":"Parkinsonism Relat Disord"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-13-113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2377-13-113\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-13-113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-13-113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:15:43Z","timestamp":1630545343000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/1471-2377-13-113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,2]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["839"],"URL":"https:\/\/doi.org\/10.1186\/1471-2377-13-113","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,2]]},"assertion":[{"value":"26 January 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"113"}}